Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Salvia Divinorum/Anxiety Disorders

Salvia Divinorum for Anxiety Disorders

1 paper and 0 clinical trials exploring salvia divinorum as a treatment for anxiety disorders.

CompoundDiterpenoid

Salvia Divinorum

A specialized plant species that produces salvinorin A, a potent and selective kappa-opioid agonist with intense, short-lived effects.

Full Salvia Divinorum profile
Indication300 million worldwide

Anxiety Disorders

Anxiety disorders, affecting around 300 million people globally, are among the most prevalent mental health conditions. Emerging clinical research suggests that various psychedelics, including psilocybin, MDMA, and LSD, hold potential for alleviating anxiety symptoms through innovative therapeutic approaches.

Full Anxiety Disorders profile

Academic Research

1 paper
Open Accessindividual

Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports

This large-scale data-analytic study compared the semantic similarity of psychoactive trip reports (n≈15,000) and narrative accounts Near-Death Experiences (n=625), and found that ketamine (followed by salvinorin A and DMT) bared the most resemblance to the experience of 'dying'. The authors speculate that a ketamine model of Near-Death Experiences may indicate a neuroprotective function of endogenous NMDA antagonists released in the proximity of death.

Published
March 1, 2019
Journal
Consciousness and Cognition
Authors
Martial, C., Cassol, H., Charland-Verville, V, Erowid, E., Pallavicini, C., Sanz, C., Vivo, R. M, Zamberlan, F., Erowid, F., Laureys, S., Greyson, B., Tagliazucchi, E.

Clinical Trials

0 trials

No clinical trials have been tagged with both Salvia Divinorum and Anxiety Disorders yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Salvia Divinorum papers Search all Anxiety Disorders trials Full Salvia Divinorum profile Full Anxiety Disorders profile